home / stock / bcli / bcli quote
Last: | $0.545 |
---|---|
Change Percent: | 1.9% |
Open: | $0.515 |
Close: | $0.545 |
High: | $0.5563 |
Low: | $0.515 |
Volume: | 189,970 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.545 | $0.515 | $0.545 | $0.5563 | $0.515 | 189,970 | 04-24-2024 |
$0.525 | $0.536 | $0.525 | $0.5588 | $0.51 | 166,413 | 04-23-2024 |
$0.5401 | $0.538 | $0.5401 | $0.5823 | $0.5109 | 367,454 | 04-22-2024 |
$0.532 | $0.5 | $0.532 | $0.61 | $0.4523 | 1,007,163 | 04-19-2024 |
$0.5143 | $0.5634 | $0.5143 | $0.59 | $0.4512 | 1,080,653 | 04-18-2024 |
$0.5408 | $0.525 | $0.5408 | $0.5877 | $0.525 | 528,799 | 04-17-2024 |
$0.5271 | $0.5181 | $0.5271 | $0.57 | $0.45 | 628,134 | 04-16-2024 |
$0.5487 | $0.5918 | $0.5487 | $0.6 | $0.537 | 594,675 | 04-15-2024 |
$0.584 | $0.5847 | $0.584 | $0.62 | $0.583 | 264,997 | 04-12-2024 |
$0.5771 | $0.59 | $0.5771 | $0.67 | $0.5353 | 1,392,123 | 04-11-2024 |
$0.6015 | $0.63 | $0.6015 | $0.6353 | $0.5805 | 1,099,787 | 04-10-2024 |
$0.5825 | $0.73 | $0.5825 | $0.74 | $0.57 | 4,721,544 | 04-09-2024 |
$0.73 | $0.683 | $0.73 | $0.75 | $0.6525 | 2,863,445 | 04-08-2024 |
$0.651 | $0.651 | $0.651 | $0.685 | $0.6298 | 624,560 | 04-05-2024 |
$0.675 | $0.6748 | $0.675 | $0.7165 | $0.65 | 717,358 | 04-04-2024 |
$0.6893 | $0.71 | $0.6893 | $0.7199 | $0.6671 | 943,277 | 04-03-2024 |
$0.719 | $0.74 | $0.719 | $0.7488 | $0.67 | 613,110 | 04-02-2024 |
$0.7399 | $0.6085 | $0.7399 | $0.75 | $0.5895 | 1,460,038 | 04-01-2024 |
$0.5647 | $0.58 | $0.5647 | $0.5999 | $0.484 | 649,965 | 03-29-2024 |
$0.5647 | $0.58 | $0.5647 | $0.5999 | $0.484 | 649,965 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn PR Newswire Bob Dagher , MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NE...
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire NEW YORK , April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegener...
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS PR Newswire NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes ...